Mar. 6 at 5:28 PM
$IOVA
You can tell that it doesn’t take much to become an analyst nowadays.
The analyst at UVS raised the price target for
$IOVA from
$2 to
$4 how genius of him . They just heard the management projecting future annual earnings in excess of
$10 billion and succeeding in the first year of commercialisation building all own facilities and infrastructures. The asset of this company is basically evolution’s way of fighting the cancer using the technology to enhance it billion times t won’t be too long from here to see
$IOVA dominate the solid cancer field. lowest Mc of 2000,000,000s whereas $
$NUVL , holding the NDAon NSCLC at aluation of 8,000,000,000+ while Ivan has the best in class data To date. Beside.
$NUVL has yet to prove that Works some varieties of cancers.
